
浏览全部资源
扫码关注微信
1.苏州大学 附属张家港医院,江苏 张家港 215600
2.江苏省中医药防治肿瘤协同创新中心,南京 210023
3.南京中医药大学 中医学院·中西医结合学院,南京 210023
沈政洁,博士,主治中医师,从事中医抗肿瘤的临床及机制研究,E-mail: szjtcm@126.com
左云,博士,主任医师,从事肿瘤防治的临床及机制研究,E-mail: zuoyun1@163.com
收稿日期:2021-12-19,
网络出版日期:2022-02-08,
纸质出版日期:2022-07-05
移动端阅览
沈政洁,黎思苑,徐丽贤等.消癌解毒方含药血清增强NK细胞杀伤结肠癌的作用及机制[J].中国实验方剂学杂志,2022,28(13):85-91.
SHEN Zhengjie,LI Siyuan,XU Lixian,et al.Xiaoai Jiedu Prescription-containing Serum Enhances Lethal Effect of NK Cells on Colon Cancer Cells[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(13):85-91.
沈政洁,黎思苑,徐丽贤等.消癌解毒方含药血清增强NK细胞杀伤结肠癌的作用及机制[J].中国实验方剂学杂志,2022,28(13):85-91. DOI: 10.13422/j.cnki.syfjx.20220822.
SHEN Zhengjie,LI Siyuan,XU Lixian,et al.Xiaoai Jiedu Prescription-containing Serum Enhances Lethal Effect of NK Cells on Colon Cancer Cells[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(13):85-91. DOI: 10.13422/j.cnki.syfjx.20220822.
目的
2
探讨消癌解毒方含药血清对自然杀伤(NK)细胞杀伤结肠癌细胞的增强作用及分子机制。
方法
2
消癌解毒方含药血清(0.1%、0.5%、1%、5%、10%)处理HCT-116细胞、NK-92MI细胞24 h,噻唑蓝(MTT)比色法检测其对细胞增殖的影响。选取低体积分数(0.1%、0.5%、1%)含药血清处理共培养的HCT-116细胞、NK-92MI细胞24 h,钙黄绿素-乙酰甲酯/碘化丙啶(Calcein-AM/PI)双染检测NK细胞对结肠癌细胞杀伤作用;流式细胞仪检测结肠癌细胞凋亡;蛋白免疫印迹法(Western blot)检测凋亡、信号传导及转录激活蛋白4(STAT4)通路相关蛋白表达;酶联免疫吸附测定法(ELISA)检测干扰素(IFN)-
γ
分泌。
结果
2
MTT比色法显示,与空白组比较,消癌解毒方含药血清(5%、10%)能有效抑制HCT-116、NK-92MI细胞增殖(
P
<
0.01),但消癌解毒方含药血清(0.1%、0.5%、1%)对细胞增殖无明显影响。与空白组比较,消癌解毒方含药血清(0.1%、0.5%、1%)呈浓度依赖性的增强NK细胞对结肠癌细胞的杀伤活性,并诱导结肠癌细胞凋亡(
P
<
0.01)。Western blot显示,与空白组比较,消癌解毒方含药血清能下调B细胞淋巴瘤-2(Bcl-2)、Bcl-2相关xl蛋白(Bcl-xl)表达,上调Bcl-2相关X蛋白(Bax)表达(
P
<
0.05,
P
<
0.01);与共培养组比较,消癌解毒方含药血清(0.1%、0.5%、1%)能激活p-STAT4磷酸化,促进IFN-
γ
表达(
P
<
0.05)。ELISA显示,与空白组比较,消癌解毒方含药血清(0.1%、0.5%、1%)能提高IFN-
γ
分泌量(
P
<
0.01)。
结论
2
消癌解毒方含药血清增强NK细胞杀伤结肠癌细胞活性的机制可能与激活STAT4通路,增加NK细胞IFN-
γ
分泌量,下调Bcl-xl、Bcl-2表达,上调Bax表达,进而促进结肠癌细胞凋亡相关。
Objective
2
To explore the influence of Xiaoai Jiedu prescription (XJP)-containing serum on natural killer (NK) cells′ lethal effect on colon cancer cells and the molecular mechanism.
Method
2
XJP-containing serum (0.1%, 0.5%, 1%, 5%, 10%) was used to treat HCT-116 cells and NK-92MI cells respectively for 24 h, and methyl thiazolyl tetrazolium (MTT) assay was employed to detect cell proliferation. Then, low-concentration (0.1%, 0.5%, 1%) XJP-containing serum was selected to treat co-cultured HCT-116 cells and NK-92MI cells for 24 h and calcein acetoxymethyl ester/propidium iodide (Calcein-AM/PI) was applied to detect the killing effect of NK cells on colon cancer cells. Flow cytometry was used to detect apoptosis of colon cancer cells, Western blot the expression of apoptosis-related proteins and signal transducer and activator of transcription 4 (STAT4) pathway-related proteins, and enzyme-linked immunosorbent assay (ELISA) the secretion of interferon (IFN)-
γ
.
Result
2
High-concentration (5%, 10%) XJP-containing serum inhibited the proliferation of HCT-116 and NK-92MI cells (
P
<
0.01), while low-concentration (0.1%, 0.5%, 1%) XJP-containing serum had no obvious influence on cell proliferation compared with the blank group. As compared with the blank group, low-concentration XJP-containing serum enhanced the killing activity of NK cells against colon cancer cells in a concentration-dependent manner (
P
<
0.01), and induced apoptosis of colon cancer cells (
P
<
0.01). Moreover, XJP-containing serum (0.1%, 0.5%, 1%) down-regulated the expression of B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl), and up-regulated the expression of Bcl-2-associated X (Bax) compared with the blank group (
P
<
0.05,
P
<
0.01). Compared with the co-culture group, XJP-containing serum (0.1%, 0.5%, 1%) increased the expression of p-STAT4 and IFN-
γ
(
P
<
0.05). ELISA result showed that XJP-containing serum (0.1%, 0.5%, 1%) raised IFN-
γ
secretion (
P
<
0.01).
Conclusion
2
XJP-containing serum can enhance the activity of NK cells to kill colon cancer cells. The mechanism is the likelihood that it activates STAT4 pathway, increases IFN-
γ
secretion by NK cells, down-regulates the expression of Bcl-xl and Bcl-2, and up-regulates the expression of Bax, thereby promoting the apoptosis of colon cancer cells.
CHEN W , ZHENG R , BAADE P D , et al . Cancer statistics in China, 2015 [J]. CA Cancer J Clin , 2016 , 66 ( 2 ): 115 - 132 .
田传鑫 , 赵磊 . 结直肠癌及结直肠癌肝转移流行病学特点 [J]. 中华肿瘤防治杂志 , 2021 , 28 ( 13 ): 1033 - 1038 .
LE D , DURHAM J N , SMITH K N , et al . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade [J]. Science , 2017 , 357 ( 6349 ): 409 - 413 .
ANDRE T , SHIU K K , KIM T W , et al . Pembrolizumab in microsatellite-instability-high advanced colorectal cancer [J]. N Engl J Med , 2020 , 383 ( 23 ): 2207 - 2218 .
LE D , KIM T W , VAN CUTSEM E , et al . Phase Ⅱopen-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164 [J]. J Clin Oncol , 2020 , 38 ( 1 ): 11 - 19 .
MYERS J A , MILLER J S . Exploring the NK cell platform for cancer immunotherapy [J]. Nat Rev Clin Oncol , 2021 , 18 ( 2 ): 85 - 100 .
HUNTINGTON N D , CURSONS J , RAUTELA J . The cancer-natural killer cell immunity cycle [J]. Nat Rev Cancer , 2020 , 20 ( 8 ): 437 - 454 .
程海波 , 沈卫星 , 姚志华 , 等 . 基于癌毒病机理论的消癌解毒方抗肿瘤研究进展 [J]. 南京中医药大学学报 , 2014 , 30 ( 6 ): 593 - 595 .
沈政洁 , 程海波 , 沈卫星 , 等 . 肿瘤炎性微环境与“癌毒”病机相关性探讨 [J]. 北京中医药大学学报 , 2015 , 38 ( 1 ): 14 - 17 .
吴勉华 . 吴勉华效方治验——消癌解毒方 [J]. 江苏中医药 , 2021 , 53 ( 9 ): 1 - 2 .
周肸 , 张丹 , 钱海华 , 等 . 消癌解毒方治疗肠癌术后临床研究 [J]. 南京中医药大学学报 , 2020 , 36 ( 6 ): 826 - 830 .
陈海彬 , 周红光 , 程海波 , 等 . 消癌解毒方对中晚期恶性肿瘤患者免疫功能的影响 [J]. 南京医科大学学报:自然科学版 , 2009 , 29 ( 9 ): 1257 - 1259 .
周芷若 , 俞晓忆 , 贾志荣 , 等 . 消癌解毒方对CT26荷瘤小鼠抗结肠癌药效及机制研究 [J]. 中华中医药学刊 , 2018 , 36 ( 7 ): 1625 - 1629 .
谭佳妮 , 石文静 , 沈卫星 , 等 . 消癌解毒方对结肠癌的抑制作用及对Treg细胞的影响 [J]. 南京中医药大学学报 , 2017 , 33 ( 5 ): 515 - 518 .
程海波 , 李柳 , 吴勉华 , 等 . 癌毒病机理论辨治肠癌探讨 [J]. 时珍国医国药 , 2017 , 28 ( 10 ): 2487 - 2488 .
魏小曼 , 程海波 . 基于癌毒病机理论的大肠癌治则治法 [J]. 中华中医药杂志 , 2020 , 35 ( 12 ): 6182 - 6184 .
YANG Y . Cancer immunotherapy: Harnessing the immune system to battle cancer [J]. J Clin Invest , 2015 , 125 ( 9 ): 3335 - 3337 .
王梦晨 , 张雪涟 , 陈向东 , 等 . 灵芝三萜与灵芝多糖抗肿瘤作用及其机制研究进展 [J]. 中国实验方剂学杂志 , 2022 , doi: 10.13422/j.cnki.syfjx.20220431 http://dx.doi.org/10.13422/j.cnki.syfjx.20220431 .
周钱梅 , 苏式兵 . 参芪扶正注射液通过肿瘤相关巨噬细胞提高人乳腺癌MDA-MB-231细胞对顺铂的敏感性 [J]. 中国实验方剂学杂志 , 2020 , 26 ( 4 ): 76 - 81 .
许晓燕 , 罗霞 , 宋怡 , 等 . 灵芝多糖通过调节内皮细胞ICAM-1表达促进T淋巴细胞肿瘤浸润的研究 [J]. 中国中药杂志 , 2021 , 46 ( 19 ): 5072 - 5079 .
白璐 , 苏锐 , 权兴苗 , 等 . 八珍汤加减对胃癌新辅助化疗患者营养状况和免疫功能的影响 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 11 ): 117 - 122 .
罗文 , 王涛 , 熊国江 , 等 . 补中益气汤加减对非小细胞肺癌术后化疗患者VEGF,IGF-1,TGF- β 1 ,免疫功能的影响及安全性分析 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 16 ): 90 - 95 .
卢泰成 , 李杰 , 朱广辉 , 等 . 基于免疫重塑探讨活血药、益气活血药对肿瘤转移影响差异 [J]. 中国中药杂志 , 2021 , 46 ( 11 ): 2766 - 2772 .
吴海斯 . NK细胞抗肿瘤应答的调控机制研究 [D]. 深圳 : 中国科学院大学(中国科学院深圳先进技术研究院) , 2020 .
彭六生 . NK细胞在胃癌中的应答调控及作用研究 [D]. 重庆 : 第三军医大学 , 2014 .
连晶瑶 , 李红 , 黄岚 , 等 . 体外扩增人脐带血来源的NK细胞对食管癌细胞的促凋亡作用 [J]. 中国肿瘤生物治疗杂志 , 2017 , 24 ( 2 ): 117 - 121 .
GOTTHARDT D , SEXL V . STATs in NK-cells: The Good, the Bad, and the Ugly [J]. Front Immunol , 2017 , doi: 10.3389/fimmu.2016.00694 http://dx.doi.org/10.3389/fimmu.2016.00694 .
0
浏览量
16
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621